Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Gynecol Endocrinol ; 22(10): 557-63, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17135035

ABSTRACT

BACKGROUND: Arterial hypertension and postmenopausal reduction of estrogen levels may be involved in modifications of the stiffness of large arteries. OBJECTIVES: To evaluate the pulse-wave velocity (PWV) and indirectly the arterial stiffness in hypertensive postmenopausal women submitted to hormone therapy with estradiol alone or combined with norethisterone acetate. SUBJECTS: Forty-five hypertensive postmenopausal women were double-blindly, randomly assigned to three arms of treatment: placebo (group I); estradiol 2 mg/day (group II); or estradiol 2 mg/day and norethisterone acetate 1 mg/day (group III). METHODS: Arterial stiffness was assessed from PWV measurements of the common carotid and femoral arteries (CF-PWV) and the common carotid and radial arteries (CR-PWV) obtained using the automatic Complior(R) device, taken at baseline and after 12 weeks of treatment. RESULTS: After the 12-week treatment, values of CF-PWV and CR-PWV were not significantly different (p = 0.910 and p = 0.736, respectively) among the groups. Systolic blood pressure showed a positive correlation with CF-PWV in groups II and III (p = 0.02 and p < 0.001, respectively). CONCLUSIONS: PWV and arterial stiffness in postmenopausal hypertensive women did not reduce over a 12-week treatment with estradiol alone compared with the same period of treatment with estradiol combined with norethisterone acetate.


Subject(s)
Blood Flow Velocity/drug effects , Estradiol/pharmacology , Hypertension/physiopathology , Norethindrone/analogs & derivatives , Postmenopause/drug effects , Pulse , Blood Pressure/drug effects , Carotid Arteries/physiopathology , Double-Blind Method , Drug Combinations , Estradiol/administration & dosage , Female , Humans , Hypertension/blood , Middle Aged , Norethindrone/administration & dosage , Norethindrone/pharmacology , Norethindrone Acetate , Placebos , Postmenopause/blood , Vascular Resistance/drug effects
2.
Heart ; 90(7): 777-81, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15201248

ABSTRACT

BACKGROUND: Left ventricular function changes in the postmenopausal state. However, there are conflicting reports about the effects of oestrogen on left ventricular diastolic function in postmenopausal women. OBJECTIVE: To evaluate the acute and chronic effects of oestradiol in physiological doses on diastolic heart function in hypertensive postmenopausal women with left ventricular diastolic dysfunction. METHODS: A prospective, randomised, double blind, placebo controlled study was used to evaluate the effects of oestradiol in 34 hypertensive women with left ventricular dysfunction. The acute effects of a single 1 mg oral dose of oestradiol or placebo were determined after 90 minutes. The chronic effects of 1 mg oestradiol orally/day or placebo were determined after 12 weeks. Diastolic functional indices (mitral flow and pulmonary venous flow) were assessed by Doppler echocardiography. RESULTS: Though an appropriate serum concentration was achieved, no acute effect of oestradiol administration on left ventricular diastolic function was identified. After 12 weeks of treatment the following changes (mean (SD)) were identified in the oestradiol group: a decrease in isovolumic relaxation time from 127 (23) to 106 (16) ms (p < 0.001), and in the deceleration time of the mitral E wave from 260 (42) to 238 (20) ms (p < 0.05); and an increase in the E/A ratio from 0.8 (0.2) (basal) to 1.0 (0.2) after 12 weeks (p < 0.001). CONCLUSIONS: Hypertensive postmenopausal women who had hormone replacement therapy over a period of 12 weeks had significant improvement in left ventricular diastolic function. No changes were identified following acute administration.


Subject(s)
Estradiol/pharmacology , Hypertension/complications , Postmenopause/drug effects , Ventricular Dysfunction, Left/drug therapy , Adult , Aged , Blood Flow Velocity , Blood Pressure/drug effects , Body Mass Index , Diastole , Double-Blind Method , Estradiol/administration & dosage , Female , Heart Rate/drug effects , Humans , Hypertension/physiopathology , Middle Aged , Observer Variation , Prospective Studies , Ultrasonography, Doppler , Ventricular Dysfunction, Left/physiopathology , Ventricular Function, Left/drug effects
3.
Gynecol Endocrinol ; 19(5): 282-92, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15726917

ABSTRACT

The objective of this study was to assess the acute and chronic effects of estradiol on the myocardial performance index (MPI) in hypertensive postmenopausal women. There are conflicting reports on the effects of estrogen on left ventricular function in postmenopausal women, and we are unaware of any study on the myocardial performance index in the postmenopausal state. We undertook a prospective, randomized, double-blind, placebo-controlled study in 34 women, distributed into an estradiol group or a placebo group. After 90 min and at 12 weeks of administration of 1 mg of oral estradiol we evaluated, by Doppler echocardiography, its effects on the MPI. The estradiol group showed no alteration in the MPI after 90 min of the administration of estradiol. On the other hand, after 12 weeks of treatment we observed a statistically significant decrease of isovolumic relaxation time, from 127+/-23 ms to 106+/-16 ms (p < 0.001 and of the MPI from 0.63+/-0.13 to 0.48+/-0.09 (p < 0.01) and an increase in ejection time, from 297+/-32 ms to 330+/-31 ms (p < 0.01). In conclusion, estrogen replacement therapy over a period of 12 weeks showed a significant improvement in the MPI in hypertensive postmenopausal women, whereas the acute administration did not have any effect.


Subject(s)
Echocardiography, Doppler , Estradiol/administration & dosage , Estrogen Replacement Therapy , Hypertension/drug therapy , Myocardium , Postmenopause , Adult , Aged , Double-Blind Method , Female , Follicle Stimulating Hormone/blood , Humans , Luteinizing Hormone/blood , Middle Aged , Placebos , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...